Design of Boron-Based Peptidomimetics Leads to Potent Inhibitors of Human ClpP and ClpXP

<p><a>Boronic acids have attracted the attention of synthetic and medicinal chemists due to boron’s ability to modulate enzyme function. </a>Recently, we demonstrated that boron-containing amphoteric building blocks facilitate the discovery of bioactive aminoboronic acids. Herein, we have augmented this capability with a <i>de novo</i> library design and virtural screening platform modified for covalent ligands. This technique has allowed us to rapidly design and identify a series of α-aminoboronic acids as the first inhibitors of human ClpXP, which is responsible for the degradation of misfolded proteins.</p>